Related Experiment Video
Updated: Jun 14, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Combinatorial latency reactivation for HIV-1 subtypes and variants.
John C Burnett1, Kwang-Il Lim, Arash Calafi
1Department of Chemical Engineering and Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720, USA.
A combination of prostratin and suberoylanilide hydroxamic acid (SAHA) effectively reactivates latent HIV-1 across multiple subtypes. This synergistic drug combination offers a promising strategy for purging the viral reservoir in patients.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- HIV-1 eradication requires purging latent viral reservoirs.
- Current latency-reversing agents show limitations against diverse viral subtypes and mutations.
Purpose of the Study:
- To evaluate a novel combination therapy for HIV-1 latency reversal.
- To assess the efficacy of prostratin and SAHA against various HIV-1 subtypes and integration sites.
Main Methods:
- Utilized primary CD4(+) and Jurkat cell-based in vitro HIV-1 latency models.
- Tested single-agent and combination therapies (prostratin + SAHA).
- Identified proviral integration sites in latent Jurkat cell clones.
Main Results:
- Single-agent therapies were ineffective against most HIV-1 subtypes.
- The prostratin + SAHA combination demonstrated synergistic activity across HIV-1 subtypes A, B, C, D, and F.
- The drug combination showed selective effects, not significantly enhancing nearby endogenous gene expression.
Conclusions:
- Combination therapy with prostratin and SAHA is a potent strategy for HIV-1 latency reversal.
- This approach overcomes limitations of single-agent therapies and targets diverse viral strains.
- The selective action of the drug combination suggests a potential for targeted reservoir purging.
Related Concept Videos
Size and Structure of Viral Genomes
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Viral Recombination
Retroviruses
Antiviral Nucleoside Inhibitors

